JP2012050465A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012050465A5 JP2012050465A5 JP2011270236A JP2011270236A JP2012050465A5 JP 2012050465 A5 JP2012050465 A5 JP 2012050465A5 JP 2011270236 A JP2011270236 A JP 2011270236A JP 2011270236 A JP2011270236 A JP 2011270236A JP 2012050465 A5 JP2012050465 A5 JP 2012050465A5
- Authority
- JP
- Japan
- Prior art keywords
- human
- inhibitor
- mammal
- dna segment
- segment encoding
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 101001081555 Homo sapiens Plasma protease C1 inhibitor Proteins 0.000 claims 39
- 102000044507 human SERPING1 Human genes 0.000 claims 39
- 102000055157 Complement C1 Inhibitor Human genes 0.000 claims 16
- 108700040183 Complement C1 Inhibitor Proteins 0.000 claims 16
- 241000124008 Mammalia Species 0.000 claims 15
- 210000004216 mammary stem cell Anatomy 0.000 claims 15
- 239000008267 milk Substances 0.000 claims 14
- 210000004080 milk Anatomy 0.000 claims 14
- 235000013336 milk Nutrition 0.000 claims 14
- 210000004027 cell Anatomy 0.000 claims 9
- 239000008194 pharmaceutical composition Substances 0.000 claims 9
- 108010076504 Protein Sorting Signals Proteins 0.000 claims 8
- 210000000481 breast Anatomy 0.000 claims 8
- 230000001105 regulatory effect Effects 0.000 claims 8
- 238000000034 method Methods 0.000 claims 6
- 201000007120 C1 inhibitor deficiency Diseases 0.000 claims 4
- 206010019860 Hereditary angioedema Diseases 0.000 claims 4
- 238000005342 ion exchange Methods 0.000 claims 4
- 229910021645 metal ion Inorganic materials 0.000 claims 4
- 102000003839 Human Proteins Human genes 0.000 claims 3
- 108090000144 Human Proteins Proteins 0.000 claims 3
- 238000005349 anion exchange Methods 0.000 claims 3
- 238000005341 cation exchange Methods 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 241000283973 Oryctolagus cuniculus Species 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 235000013305 food Nutrition 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 210000005075 mammary gland Anatomy 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 230000009261 transgenic effect Effects 0.000 claims 1
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17931000P | 2000-01-31 | 2000-01-31 | |
| EP00200320.0 | 2000-01-31 | ||
| US60/179,310 | 2000-01-31 | ||
| EP00200320 | 2000-01-31 | ||
| US18758000P | 2000-03-07 | 2000-03-07 | |
| EP00200810 | 2000-03-07 | ||
| US60/187,580 | 2000-03-07 | ||
| EP00200810.0 | 2000-03-07 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001557910A Division JP2003521914A (ja) | 2000-01-31 | 2001-01-31 | トランスジェニック哺乳動物の乳汁に産生されるｃ１インヒビター |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014075150A Division JP2014121337A (ja) | 2000-01-31 | 2014-04-01 | トランスジェニック哺乳動物の乳汁に産生されるｃ１インヒビター |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012050465A JP2012050465A (ja) | 2012-03-15 |
| JP2012050465A5 true JP2012050465A5 (enExample) | 2013-07-04 |
Family
ID=27439989
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011270236A Pending JP2012050465A (ja) | 2000-01-31 | 2011-12-09 | トランスジェニック哺乳動物の乳汁に産生されるｃ１インヒビター |
| JP2014075150A Pending JP2014121337A (ja) | 2000-01-31 | 2014-04-01 | トランスジェニック哺乳動物の乳汁に産生されるｃ１インヒビター |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014075150A Pending JP2014121337A (ja) | 2000-01-31 | 2014-04-01 | トランスジェニック哺乳動物の乳汁に産生されるｃ１インヒビター |
Country Status (4)
| Country | Link |
|---|---|
| US (2) | US7067713B2 (enExample) |
| JP (2) | JP2012050465A (enExample) |
| BE (1) | BE2010C040I2 (enExample) |
| FR (1) | FR10C0054I2 (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL376318A1 (en) * | 2002-10-17 | 2005-12-27 | Pharming Intellectual Property B.V. | Protein modification |
| HUE052154T2 (hu) * | 2003-05-16 | 2021-04-28 | Pharming Intellectual Property B V | Rövid felezési idejû C1 inhibitor tranziens kezeléshez |
| EP1858542A4 (en) * | 2005-02-24 | 2009-08-19 | Joslin Diabetes Center Inc | COMPOSITIONS AND METHOD FOR THE TREATMENT OF VASPEREPERMABILITY |
| HRP20110622T1 (hr) | 2005-12-21 | 2011-09-30 | Pharming Intellectual Property B.V. | Upotreba inhibitora c1 u sprječavanju ishemijsko-reperfuzijske ozljede |
| FR2901707B1 (fr) * | 2006-05-31 | 2017-09-29 | Lab Francais Du Fractionnement | Composition de facteur vii recombinant ou transgenique, chaque molecule de facteur vii possedant deux sites de n-glycosylation a motifs glycanniques definis |
| FR2904558B1 (fr) * | 2006-08-01 | 2008-10-17 | Lab Francais Du Fractionnement | "composition de facteur vii recombinant ou transgenique, presentant majoritairement des formes glycanniques biantennees, bisialylees et non fucosylees" |
| US20100119512A1 (en) * | 2007-01-25 | 2010-05-13 | Joslin Diabetes Center | Methods of diagnosing, treating, and preventing increased vascular permeability |
| CN111044725B (zh) | 2013-01-20 | 2024-03-29 | 武田药品工业株式会社 | 缓激肽介导的病症的评估和治疗 |
| BR112015019341A2 (pt) | 2013-02-13 | 2017-08-22 | Lab Francais Du Fractionnement | Anticorpo anti-tnf-alfa, composição que compreende o anticorpo, método para produzir uma população de anticorpos, células epiteliais da glândula mamária, mamífero não humano transgênico, e, composição de anticorpo anti-tnf monoclonal |
| EP2956003A2 (en) | 2013-02-13 | 2015-12-23 | Laboratoire Français du Fractionnement et des Biotechnologies | Proteins with modified glycosylation and methods of production thereof |
| SI2968434T1 (sl) | 2013-03-15 | 2017-11-30 | Shire Viropharma Incorporated, | C1-INH sestavki za uporabo pri preprečevanju in zdravljenju hereditarnega angioedema (HAE) |
| KR20250066486A (ko) * | 2013-10-21 | 2025-05-13 | 다케다 파머수티컬 컴패니 리미티드 | 혈장 칼리크레인 시스템 바이오마커를 결정하기 위한 검정법 |
| PT3060908T (pt) | 2013-10-21 | 2021-05-27 | Dyax Corp | Diagnóstico e tratamento de doenças autoimunes |
| CA2933612A1 (en) * | 2013-12-24 | 2015-07-02 | Lfb Usa, Inc. | Transgenic production of heparin |
| SG10202012832VA (en) | 2015-05-28 | 2021-01-28 | Univ Cornell | Adeno-associated virus mediated delivery of c1ei as a therapy for angioedema |
| HK1250623A1 (zh) * | 2015-05-28 | 2019-01-11 | Cornell University | 腺相关病毒介导的c1ei递送作为用於血管性水肿的疗法 |
| FR3038517B1 (fr) | 2015-07-06 | 2020-02-28 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | Utilisation de fragments fc modifies en immunotherapie |
| JP6903648B2 (ja) | 2015-10-19 | 2021-07-14 | ダイアックス コーポレーション | 切断高分子量キニノーゲンを検出するイムノアッセイ |
| EP3493832A1 (en) | 2016-08-05 | 2019-06-12 | CSL Behring GmbH | Pharmaceutical formulations of c1 esterase inhibitor |
| CA3061279A1 (en) * | 2017-05-16 | 2018-11-22 | Octapharma Ag | C1-esterase inhibitor preparation |
| WO2019166556A1 (en) * | 2018-02-28 | 2019-09-06 | Pharming Intellectual Property B.V. | Treatment and prevention of pre-eclampsia |
| EP3895726A1 (en) | 2020-04-17 | 2021-10-20 | Pharming Intellectual Property BV | Using c1 esterase inhibitor to treat viral infection-related acute respiratory distress |
| CA3225079A1 (en) | 2021-07-09 | 2023-01-12 | Bruno Giannetti | Using c1 esterase inhibitor to treat viral infection-related symptoms |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2601034B1 (fr) | 1986-07-03 | 1989-11-17 | Pasteur Institut | Inhibiteur de l'activite de la c1-esterase plasmatique (c1-inhibiteur) et d'autres enzymes proteolytiques du groupe des proteases a serine, son procede de preparation, acides nucleiques codant pour cet inhibiteur, methodes de detection d'affections correlees aux defauts dudit inhibiteur a l'aide d'anticorps ou de sondes nucleotidiques et medicaments contenant ledit inhibiteur de synthese |
| JPH05503001A (ja) | 1989-10-27 | 1993-05-27 | スティッチング セントラール ラボラトリウム ファン デ ブルートトランスフュジエディエンスト ファン ヘット ネデールランツェ ローデ クルイス | Ｃ１インヒビターミューティンおよびその利用 |
| US5633076A (en) * | 1989-12-01 | 1997-05-27 | Pharming Bv | Method of producing a transgenic bovine or transgenic bovine embryo |
| WO1992022320A1 (en) | 1991-06-14 | 1992-12-23 | Genentech, Inc. | C1 inhibitor variants and treating inflammatory response with c1 inhibitor |
| DE4227762A1 (de) | 1992-08-24 | 1994-03-03 | Behringwerke Ag | Verwendung eines Kallikrein-Inhibitors zur Herstellung eines Arzneimittels zur Prophylaxe und Therapie bestimmter Krankheiten |
| US6713662B1 (en) * | 1994-07-27 | 2004-03-30 | Pharming Intellectual Property B.V. | Production of collagen in the milk of transgenic mammals |
| GB9807464D0 (en) * | 1998-04-07 | 1998-06-10 | Pharming Bv | Purification of human acid µ-glucosidase |
| ES2299473T3 (es) * | 2000-01-31 | 2008-06-01 | Pharming Intellectual Property B.V. | Inhibidor de c1 humano producido en la leche de mamiferos transgenicos. |
-
2001
- 2001-01-31 US US10/181,704 patent/US7067713B2/en active Active
-
2005
- 2005-03-22 US US11/087,789 patent/US20050223416A1/en not_active Abandoned
-
2010
- 2010-12-08 BE BE2010C040C patent/BE2010C040I2/fr unknown
- 2010-12-16 FR FR10C0054C patent/FR10C0054I2/fr active Active
-
2011
- 2011-12-09 JP JP2011270236A patent/JP2012050465A/ja active Pending
-
2014
- 2014-04-01 JP JP2014075150A patent/JP2014121337A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012050465A5 (enExample) | ||
| JP2003521914A5 (enExample) | ||
| Liikanen et al. | Oncolytic adenovirus with temozolomide induces autophagy and antitumor immune responses in cancer patients | |
| Golan et al. | The role of the zinc transporter SLC30A2/ZnT2 in transient neonatal zinc deficiency | |
| Li et al. | Bone marrow mesenchymal stem cell‐derived dermcidin‐containing migrasomes enhance LC3‐associated phagocytosis of pulmonary macrophages and protect against post‐stroke pneumonia | |
| IN2014MN01781A (enExample) | ||
| ES2826123T3 (es) | Método de purificación de anticuerpos | |
| ES2659185T3 (es) | Levadura recombinante | |
| CA2398707A1 (en) | C1 inhibitor produced in the milk of transgenic mammals | |
| JP2013504589A5 (enExample) | ||
| US12173037B1 (en) | Mutant NGAL proteins and uses thereof | |
| PH12019500439A1 (en) | Monoclonal antibodies against tissue factor pathway inhibitor (tfpi) | |
| CN103153333B (zh) | 补体因子h的纯化方法 | |
| CN108779166A (zh) | 从血浆纯化蛋白质的方法 | |
| WO2014005466A1 (zh) | 改善缺铁性贫血的产品及其制备方法 | |
| Liu et al. | Palladium-Based Nanocomposites Remodel Osteoporotic Microenvironment by Bone-Targeted Hydrogen Enrichment and Zincum Repletion | |
| Manzer et al. | Targeting the BspC-vimentin interaction to develop anti-virulence therapies during Group B streptococcal meningitis | |
| AR074398A1 (es) | Anticuerpo nonoclonal o su fragmento de union a antigeno polinucleotido vector de expresion recombinante y celula huesped transformada correspondientes su uso para la preparacion de un medicamento util para el tratamiento o prevencion de anemia, composicion farmaceutica que lo comprende y proceso pa | |
| CN102441172A (zh) | 高纯度凝血酶原复合物制品冷冻干燥稳定剂 | |
| CN101744798A (zh) | 一种含钙枸橼酸盐浓缩抗凝血液透析液 | |
| Dai et al. | LATS1 inhibitor and zinc supplement synergistically ameliorates contrast-induced acute kidney injury: Induction of Metallothionein-1 and suppression of tubular ferroptosis | |
| JP2013517259A5 (enExample) | ||
| CN103330952A (zh) | 131I标记抗VEGFR2嵌合Fab及其应用 | |
| CN106380507A (zh) | 一种单克隆抗体的纯化工艺 | |
| Yeom et al. | Hepatic veno-occlusive disease may develop in secondary iron overloaded mice after allogeneic hematopoietic stem cell transplantation with total body irradiation |